SCHEMBL13678307

SCHEMBL13678307

C#CCC(c1cccc(C#N)c1)n1cc(-c2ncnc3c2CCN3)cn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 9/20 0.54
JAK1 P23458 8/20 0.54
CREBBP Q92793 1/20 0.37
RPS6KB1 P23443 4/20 0.35
JAK3 P52333 3/20 0.33
DAPK3 O43293 2/20 0.33
PAK4 O96013 2/20 0.33
ABL1 P00519 2/20 0.33
RET P07949 2/20 0.33
LTK P29376 2/20 0.33
CSNK1A1 P48729 2/20 0.33
CLK2 P49760 2/20 0.33
TNK2 Q07912 2/20 0.33
ROCK1 Q13464 2/20 0.33
DYRK1A Q13627 2/20 0.33
IKBKE Q14164 2/20 0.33
NTRK3 Q16288 2/20 0.33
NTRK2 Q16620 2/20 0.33
LRRK2 Q5S007 2/20 0.33
TAOK1 Q7L7X3 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13678309 0.86 JAK2 (0.49) JAK2JAK1CREBBPRPS6KB1JAK3
SCHEMBL10315608 0.81 JAK2 (0.61) JAK2JAK1JAK3DAPK3PAK4
SCHEMBL102811 0.80 JAK2 (0.53) JAK2JAK1JAK3DAPK3PAK4
SCHEMBL13541202 0.76 JAK2 (0.60) JAK2JAK1JAK3DAPK3PAK4
SCHEMBL19062191 0.76 CREBBP (0.40) JAK2JAK1CREBBPRPS6KB1JAK3
SCHEMBL13540942 0.74 JAK2 (0.60) JAK2JAK1JAK3DAPK3PAK4
SCHEMBL19790052 0.74 JAK2 (0.70) JAK2JAK1JAK3DAPK3PAK4
SCHEMBL13678279 0.74 JAK2 (0.70) JAK2JAK1JAK3DAPK3PAK4
Trifluoroacetic Acid SCHEMBL100597 0.73 TYRO3 (0.50) JAK2JAK1JAK3DAPK3PAK4
Trifluoroacetic Acid SCHEMBL29540688 0.73 TYRO3 (0.50) JAK2JAK1JAK3DAPK3PAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598257-B2 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors INCYTE CORPORATION (US) 2009-10-06 US disclosed
US-20070135461-A1 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer INCYTE CORPORATION 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135461-A1 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer JAK1, JAK3, MAP3K4 JAK2 4/4885JAK1 1/4885CREBBP 569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.